GoodRx reports transitioning from injectable to oral GLP-1s can simplify weight loss routines, but requires careful timing ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...
Eli Lilly this week announced it has submitted applications to US and European regulatory agencies for nasal glucagon, which, if approved, could shave minutes and stress from the current method for ...
LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...
Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier ...
"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In patients with metabolic-associated steatotic liver disease or metabolic-associated ...
LISBON, PORTUGAL — Minidose glucagon is more effective than insulin reduction for preventing exercise-induced hypoglycemia, according to a new study in patients with type 1 diabetes. "When initiated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback